Nirsevimab use may reduce infant hospitalizations due to RSV by 82 percent: Lancet Dr. Kamal Kant Kohli3 May 2024 7:00 PM ISTNirsevimab use may reduce infant hospitalizations due to respiratory syncytial virus (RSV) by 82 percent, shows real world evidence published in The...
Submit post-marketing safety data of Belumosudil in Chronic graft versus host disease: CDSCO Panel Tells Sanofi Dr. Divya Colin21 April 2024 6:00 PM ISTNew Delhi: Responding to the proposal presented by the drug major Sanofi to import and market Belumosudil tablets 200 mg, the Subject Expert Committee...
Innate Pharma announces advancement of Sanofi-developed NK Cell Engager SAR443579/ IPH6101 progressing to Phase 2 for blood cancer patients Ruchika Sharma15 April 2024 3:17 PM ISTFrance: Innate Pharma SA has announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial...
Sanofi new polio vaccine gets nod in India Ruchika Sharma6 April 2024 3:00 PM ISTNew Delhi: Drug giant Sanofi has received a nod for an alternative injectable vaccine, IMOVAX-Polio, to replace the widely used Inactivated Polio...
AstraZeneca-Sanofi Beyfortus approved in Japan for prevention of RSV disease in infants Ruchika Sharma31 March 2024 12:30 PM ISTCambridge: AstraZeneca and Sanofi's Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in Japan for the prophylaxis of...
Dr Reddy's Labs to promote, distribute Sanofi paediatric, adult vaccine brands in India Ruchika Sharma29 March 2024 2:25 PM ISTThese brands saw combined sales of approx. Rs 426 crores as per IQVIA MAT February 2024.
Sanofi Gets CDSCO Panel Nod To Import, Market Nirsevimab to Treat Respiratory Syncytial Virus Disease Dr. Divya Colin27 March 2024 6:00 PM ISTNew Delhi: Pharmaceutical major Sanofi Healthcare India has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug...
CDSCO Panel Approves Sanofi's Protocol Amendment Proposal For Study of SAR443122 in Ulcerative Colitis Dr. Divya Colin17 March 2024 5:45 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Sanofi gets CDSCO Panel nod to study Antidiabetic Drug Insulin Glargine and Lixisenatide Injection Dr. Divya Colin1 March 2024 6:00 PM ISTNew Delhi: The drug major Sanofi has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Sanofi Gets CDSCO Panel Nod to Study COPD drug Itepekimab Dr. Divya Colin26 Feb 2024 6:00 PM ISTNew Delhi: The drug major Sanofi has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Dupixent application accepted for priority review by USFDA for COPD with type 2 inflammation Ruchika Sharma23 Feb 2024 4:30 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License...
Sanofi consumer healthcare spin-off attracts private equity interest: Sources Ruchika Sharma21 Feb 2024 2:30 PM ISTLondon: Drugmaker Sanofi's consumer healthcare division has attracted interest from private equity funds as the French group prepares to spin out...
